Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 3/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | MTOR | P42345 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.37 |
| ▸ | ALB | P02768 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.37 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.37 |
| ▸ | POLA1 | P09884 | 1/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL350552 | 1.00 | PDE3A (0.52) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL223208 | 0.90 | PDE3A (0.54) | PDE3APDE4DSLC29A1LMNAMTOR | |
| Hydrochloric Acid SCHEMBL28104164 | 0.89 | PDE3A (0.53) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL23258348 | 0.88 | PDE3A (0.56) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL27966727 | 0.87 | PDE3A (0.54) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL12878163 | 0.85 | PDE3A (0.48) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL12891131 | 0.85 | PDE3A (0.48) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL5824290 | 0.84 | PDE3A (0.48) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL3759574 | 0.84 | POLA1 (0.44) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL19644955 | 0.82 | PDE4D (0.38) | PDE3APDE4DSLC29A1LMNAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083770-A1 | RNA COMPLEXES AND NANOSTRUCTURES FOR TREATMENT OF CANCER METASTASIS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-26 | — | — | US | disclosed |
| CN-115916142-A | Coupled terpene conjugates | 埃里格实验室公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115746073-A | Diastereoselective synthesis of phosphate derivatives and gemcitabine prodrug NUC-1031 | 努卡那有限公司 | 2023-03-07 | — | — | CN | disclosed |
| CN-108779136-B | Diastereoselective synthesis of phosphate derivatives and gemcitabine prodrug NUC-1031 | 努卡那有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-10745445-B2 | Conjugates that are configured for targeted delivery of therapeutic compounds to senescent cells | UNITY BIOTECHNOLOGY, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20180215791-A1 | CONJUGATES THAT ARE CONFIGURED FOR TARGETED DELIVERY OF THERAPEUTIC COMPOUNDS TO SENESCENT CELLS | SQUICOR CARDIOVASCULAR LLC | 2018-08-02 | — | — | US | disclosed |
| US-9969776-B2 | Drug conjugates for delivering compounds to senescent cells | UNITY BIOTECHNOLOGY, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170087252-A1 | COMPOSITIONS AND METHODS FOR DETECTING OR ELIMINATING SENESCENT CELLS TO DIAGNOSE OR TREAT DISEASE | SQUICOR CARDIOVASCULAR LLC | 2017-03-30 | — | — | US | disclosed |
| US-20160166718-A1 | COMPOSITIONS AND METHODS FOR DETECTING OR ELIMINATING SENESCENT CELLS TO DIAGNOSE OR TREAT DISEASE | UNITY BIOTECHNOLOGY, INC. | 2016-06-16 | — | — | US | disclosed |
| US-20160017033-A1 | COMPOSITIONS AND METHODS FOR DETECTING OR ELIMINATING SENESCENT CELLS TO DIAGNOSE OR TREAT DISEASE | UNITY BIOTECHNOLOGY, INC. | 2016-01-21 | — | — | US | disclosed |
| US-7326685-B2 | Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2008-02-05 | — | — | US | disclosed |
| WO-2007146401-A2 | DENATURED COLLAGEN PEPTIDES AND USES THEREOF | CELL-MATRIX, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007016450-A2 | METHODS FOR TREATING OR PREVENTING REACTIVATION OF A LATENT HERPESVIRUS INFECTION | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20050070470-A1 | Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof | ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, THE | 2005-03-31 | — | — | US | disclosed |
| EP-1131343-A4 | HYDROPHILIC SOMATOSTATIN ANALOGS | ADMINISTRATORS OFTHE TULANE UN (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1499630-A2 | STREPTAVIDIN EXPRESSED GENE FUSIONS AND METHODS OF USE THEREOF | Aletheon Pharmaceuticals, Inc. (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003050260-A2 | STREPTAVIDIN EXPRESSED GENE FUSIONS AND METHODS OF USE THEREOF | NEORX CORPORATION (US) | 2003-06-19 | — | — | WO | disclosed |
| US-6465613-B1 | ADMINISTERING A SOMATOSTATIN DERIVATIVE TO A PATIENT FOR SELECTIVELY TARGETING AND ARRESTING THE GROWTH OF AN ANGIOGENIC BLOOD VESSEL OR A CELL | TULANE UNIVERSITY | 2002-10-15 | — | — | US | disclosed |
| EP-1131343-A1 | HYDROPHILIC SOMATOSTATIN ANALOGS | THE ADMINISTRATORS OF THE TULANE UNIVERSITY EDUCATIONAL FUND (US) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000031122-A1 | HYDROPHILIC SOMATOSTATIN ANALOGS | TULANE UNIVERSITY (US) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083770-A1 | RNA COMPLEXES AND NANOSTRUCTURES FOR TREATMENT OF CANCER METASTASIS | RNMT, NSUN2, FBL | PDE3A 4353/4885PDE4D 3623/4885SLC29A1 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.